Perspective Therapeutics reported a net loss of $85.4 million for the nine months ended September 30, 2026, compared to $65.6 million in the prior year period, primarily driven by increased research and development expenses. The company significantly strengthened its balance sheet through a 2026 registered offering, ending the period with $201.7 million in cash, cash equivalents, and short-term investments.
Perspective Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $202 million which is expected to fund operations into 2028. The company reported a net loss of $24.7 million for the quarter and provided clinical updates on its lead radiopharmaceutical programs, including bamzireotide navoxetan and lapemelanotide zapixetar.
Term
Q3 2026
“We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform. With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field.”